Kodiak Sciences Inc KOD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Kodiak Sciences to Present at Three Upcoming Investor Conferences
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Trading Information
- Previous Close Price
- $108.25
- Day Range
- $103.20–112.79
- 52-Week Range
- $18.15–112.79
- Bid/Ask
- $110.00 / $111.00
- Shares Outstanding
- 65.40M
- Market Cap
- $6.99B
- Volume/Avg
- 972,262 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.kodiak.com
Valuation
Metric | KOD |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 568.75 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KOD |
|---|---|
Quick Ratio | 2.39 |
Current Ratio | 2.49 |
Interest Coverage | — |
Quick Ratio
KOD
Profitability
Metric | KOD |
|---|---|
Return on Assets (Normalized) | −73.37% |
Return on Equity (Normalized) | −268.39% |
Return on Invested Capital (Normalized) | −156.53% |
Return on Assets
KOD
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Rt>K@!? | LOCK|vf$?v | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!t>&t$^ | LOCK|j<&C | $99B | |||
| Moderna Inc MRNA | LOCK|>p&PGV | LOCK|>?> | $90B | |||
| argenx SE ADR ARGX | LOCK|jRpnrp | LOCK|Wl^ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|xvyB^?@ | LOCK|@K | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^$q^cx% | LOCK|jqZ# | $31B | |||
| Incyte Corp INCY | LOCK|#FvqGN& | LOCK|c# | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|&?@C%^ | LOCK|x@@b | $22B | |||
| BioNTech SE ADR BNTX | LOCK|zbTzGWK | LOCK|@MJ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|zT&Tb?! | LOCK|Jyc | $16B |
United States